Footnotes

• Competing interests DF: consultant – Penumbra, Codman JnJ, Medtronic, Sequent, Vascular Simulations; research support – Sequent, Microvention, Siemens. JM: consultant – Lazarus Effect, Reverse, Pulsar, Edge Therapeutics, Medina; investor – Blockade Medical, Medina, Lazarus Effect. AA: research support – Sequent and Siemens; consultant – Microvention, Johnson and Johnson, Medtronic, Penumbra, Silk Road, Stryker, Sequent; stock – Lazarus Effect and Valor. AS: consultant – Codman & Shurtleff Inc, Covidien Vascular Therapies, GuidePoint Global Consulting, Penumbra, Stryker, Pulsar Vascular, Microvention, Lazarus Effect, Blockade Medical, Reverse Medical, WL Gore & Associates, Medina Medical, Cervetech Inc, Neuroavi, Perflow Medical, Silkroad Medical, TRES Medical, Syntervention; research grants – The National Institutes of Health; financial interests – Hotspur, Intratech Medical, StimSox, Valor Medical, Blockade Medical, Lazarus Effect, Pulsar Vascular, Medina Medical Inc; national steering committees – Penumbra, 3D Separator Trial, Covidien, SWIFT PRIME Trial, LARGE Trial, POSITIVE Trial, Codman, BRAVO Trial, Neuroavi, ARISE II Trial; advisory board – Codman & Shurtleff, Covidien Neurovascular, Inter–societal Accreditation Commission. DH: consultant – Stryker; investigator – Penumbra. AT: consultant, reserach gants – Penumbra, Stryker, Codman, Covidien, Microvention, Medina, Lazarus Effect, Pulsar Vascular, Siemens; stock – Medina, Lazarus Effect, Pulsar Vascular.

• Provenance and peer review Commissioned; internally peer reviewed.